IGM Biosciences Inc. (IGMS) Reports Q4 Loss of $0.79/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall St set for higher open as AI stocks rise, oil slides
- Streamflation drives 39% of Americans to cancel streaming in 6 months
IGM Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 30, 2021 4:17 PM EDTRecommended Phase 2 Dose for IGM-2323 Expected in 2021
Initial Data from Phase 1 Trial of IGM-8444 in Solid Cancers Expected in 2021
IND Filing for IGM-7354 Planned in 2021
Company to Host Conference Call Today at 4:30 p.m. ET
MOUNTAIN VIEW, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on recent... More
